BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. The Company's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the acute treatment of agitation associated with Alzheimer’s disease and as an adjunctive treatment for Major Depressive Disorder, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.
American Stock Transfer and Trust
Ernst & Young LLP
Latham & Watkins LLP
Data Provided by Refinitiv. Minimum 15 minutes delayed.